Navigation Links
Cancer stem cells under the microscope at Albert Einstein College of Medicine symposium

May 13, 2014 (BRONX, NY) Healthy stem cells work to restore or repair the body's tissues, but cancer stem cells have a more nefarious mission: to spawn malignant tumors. Cancer stem cells were discovered a decade ago, but their origins and identity remain largely unknown.

Today, the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Albert Einstein College of Medicine of Yeshiva University hosted its second Stem Cell Symposium, focusing on cancer stem cells. Leading scientists from the U.S., Canada and Belgium discussed the latest advances in the field and highlighted the challenges of translating this knowledge into targeted cancer treatments.

"These exceptional scientists are pioneers in the field and have made enormous contributions to our understanding of the biology of stem cells and cancer," said Paul Frenette, M.D., director and chair of Einstein's Stem Cell Institute and professor of medicine and of cell biology. "Hopefully this symposium will spark productive dialogues and collaborations among the researchers who attend."

The presenters were:

  • "Cancer Stem Cells and Malignant Progression," Robert A. Weinberg, Ph.D., Daniel K. Daniel K. Ludwig Professor for Cancer Research Director, Ludwig Center of the Massachusetts Institute of Technology; Member, Whitehead Institute for Biomedical Research
  • "Towards Unification of Cancer Stem Cell and Clonal Evolution Models of Intratumoral Heterogeneity," John Dick, Ph.D., Canada Research Chair in Stem Cell Biology and senior scientist, Princess Margaret Cancer Center, University Health Network; professor of molecular genetics, University of Toronto
  • "Normal and Neoplastic Stem Cells," Irving L. Weissman, M.D., Director, Institute for Stem Cell Biology and Regenerative Medicine and Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine; Professor of Pathology and Developmental Biology, Stanford University School of Medicine
  • "Cell Fate Decisions During Tumor Formation," Leonard I. Zon, M.D., Grousbeck Professor of Pediatric Medicine, Director, Stem Cell Research Program, Howard Hughes Medical Institute/Boston Children's Hospital, Harvard Medical School
  • "Skin Stem Cells in Silence, Action and Cancer," Elaine Fuchs, Ph.D., Rebecca C. Lancefield Professor, Laboratory of Mammalian Cell Biology and Development, Howard Hughes Medical Institute/The Rockefeller University
  • "Mechanism Regulating Stemness in Skin Cancer," Cdric Blanpain, M.D., Ph.D., professor of stem cell and developmental biology, WELBIO, Interdisciplinary Research Institute, Universit Libre de Bruxelles
  • "Mouse Models of Malignant GBM: Cancer Stem Cells and Beyond," Luis F. Parada, Ph.D., professor and chairman, Diana K and Richard C. Strauss Distinguished Chair in Developmental Biology; Director, Kent Waldrep Foundation Center for Basic Neuroscience Research; Southwestern Ball Distinguished Chair in Nerve Regeneration Research, University of Texas Southwestern Medical Center


Contact: Deirdre Branley
Albert Einstein College of Medicine

Related biology news :

1. Scientists from USC and NYU design a molecule that blocks cancer growth in mice
2. Researchers identify link between colon cancer and metabolism
3. JAX researchers identify potential therapeutic target for wound-healing and cancer
4. Henry Ford researchers identify genetic factors that may aid survival from brain cancer
5. University of Chicago chosen as a center for new cancer clinical trials network
6. Current guidelines underestimate US cervical cancer incidence and older womens risk
7. New method sneaks drugs into cancer cells before triggering release
8. Investigating the role of aging and poor nutrition on colon cancer: NIH awards Einstein $3.2 million grant
9. Ability to isolate and grow breast tissue stem cells could speed cancer research
10. Molecular tumor board helps in advanced cancer cases
11. Glutamine ratio is key ovarian cancer indicator
Post Your Comments:
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology: